Streetbeat News

TCNNF

Trulieve Cannabis Corp

Employees

9,000

Industry

Medicinal and Botanical Manufacturing

Open

6.70

Mkt cap

1.3B

Volume

103K

High

6.74

P/E Ratio

-9.49

52-wk high

14.50

Low

6.40

Div yield

N/A

52-wk low

4.75

Michael Berger, a cannabis stock expert at Benzinga, highlights the burgeoning opportunities in the cannabis sector, spurred by the DEA's decision to reclassify marijuana to Schedule III, signaling a bullish outlook for cannabis stocks. Berger emphasizes the importance of cautious investment in this volatile market, recommending a diversified approach and focusing on U.S. cannabis companies like Green Thumb Industries, Trulieve Cannabis, and Curaleaf Holdings, which exhibit strong financial metrics such as free cash flow, net income, and adjusted EBITDA.

Portfolio Pulse from Jelena Martinovic

May 03, 2024 | 5:17 pm

The DEA's rescheduling of cannabis to Schedule III has caused significant market volatility for multi-state operators (MSOs), with the MSO index initially surging by 25% and then dropping by 15%. Viridian Capital Advisors highlights the impact on MSOs' credit ratings and financial health, noting Green Thumb Industries' favorable deal, Trulieve's balanced risk-return profile, and the high yields but high risks for companies like Ascend Wellness, Verano, Cresco, and Curaleaf.

Portfolio Pulse from Nicolás Jose Rodriguez

May 03, 2024 | 3:57 pm

Marijuana stocks experienced significant movements on May 1, 2024, with notable gainers including Global Hemp Group and 22nd Century Group, while losers featured AusCann Group Holdings and Canopy Growth among others. The shifts reflect volatile market conditions in the cannabis sector.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 8:30 pm

Following the DEA's announcement to reschedule cannabis, the market cap of major cannabis firms has seen significant changes. Curaleaf, Canopy, Tilray, Aurora, Green Thumb Industries, and Trulieve have experienced fluctuations in market capitalization since their public debuts. The total economic impact of regulated marijuana sales in the U.S. is expected to surpass $112.4 billion in 2024, with sales forecasted to reach $32.1 billion. Market cap growth varies among companies, with some experiencing decreases and others increases.

Portfolio Pulse from Nicolás Jose Rodriguez

May 01, 2024 | 6:25 pm

Marijuana stocks experienced significant movements with Elixinol Wellness, Item 9 Labs, and Canopy Growth among the top gainers, while Charlotte's Web Holdings and Pharmadrug led the losers. The market saw a bullish trend for cannabis companies, with notable increases in stock prices for many firms listed on both OTC and NASDAQ.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 8:30 pm

Cannabis stocks and ETFs experienced significant gains following the DEA's decision to consider rescheduling marijuana from Schedule I to Schedule III, indicating a potential shift in regulatory stance and acknowledging its medical use. This move has sparked optimism among investors about the future of the cannabis industry.

Portfolio Pulse from Jelena Martinovic

April 30, 2024 | 6:43 pm

Cannabis stocks experienced significant movements on April 26, 2024, with notable gainers including The Flowr, Heritage Cannabis Holding, and Greenlane Hldgs, among others. Conversely, companies like Rocky Mountain High, Cannabix Technologies, and Urban-gro were among the day's losers. This reflects the volatile nature of the cannabis market.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 8:30 pm

Pennsylvania is considering a state-run model for recreational marijuana distribution, similar to its liquor store system, as part of efforts to legalize cannabis. Governor Josh Shapiro supports this approach to regulate, tax, and leverage cannabis sales for state revenue and social reform, projecting $250 million annually within five years. The state Senate, traditionally GOP-dominated, is open to legalization discussions. The House proposes state-run shops, while the Senate suggests using existing medical dispensaries. Cresco Labs (CRLBF) and Trulieve (TCNNF) support the Senate's model, emphasizing market readiness and safety. The industry is divided on Shapiro's proposed 20% cannabis tax. Pennsylvania cannabis companies like Cresco Labs, Green Thumb Industries (GTBIF), and others have shown resilience, with a 3% increase in Q1 2024, despite broader economic challenges. The Pennsylvania Liquor Control Board (PLCB) is considered a potential manager for cannabis sales, highlighting the need for clear regulatory guidance.

Portfolio Pulse from Nicolás Jose Rodriguez

April 26, 2024 | 1:04 pm

Marijuana stocks experienced significant movement on April 25, 2024, with notable gainers including Cannabix Technologies, Kaya Holdings, and Urban-gro, among others. Conversely, several companies faced declines, such as Global Hemp Group, GrowGeneration, and Aurora Cannabis. This reflects the volatile nature of the marijuana stock market.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 8:30 pm

Recent analysis by Viridian Capital Advisors highlights significant differences in year-to-date performance between U.S. multi-state operators (MSOs) and Canadian licensed producers (LPs) in the cannabis sector. U.S. MSOs have seen an average return of 26.4%, while Canadian LPs have a modest 1.3%. However, excluding outliers like Trulieve Cannabis (TCNNF) and Tilray Brands (TLRY), the performance gap narrows significantly. The market's irrational behavior, influenced by regulatory changes and speculation, has led to volatility. Tilray faces challenges despite revenue gains, with a significant stock price drop after revising its financial outlook. Conversely, Trulieve's strategic success and market growth, especially with Germany's legalization and potential in Florida, position it for significant valuation increases.

Portfolio Pulse from Nicolás Jose Rodriguez

April 25, 2024 | 1:57 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.